## Maurizio Valeriani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3195017/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hypofractionated Radiation Therapy (HFRT) of Breast/Chest Wall and Regional Nodes in Locally Advanced Breast Cancer: Toxicity Profile and Survival Outcomes in Retrospective Monoistitutional Study. Clinical Breast Cancer, 2022, 22, e332-e340.	1.1	2
2	Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis. Radiologia Medica, 2022, 127, 108-116.	4.7	7
3	Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study. Minerva Urology and Nephrology, 2021, 73, 489-497.	1.3	7
4	Stereotactic and Hypofractionated Radiotherapy Associated With Immune Checkpoint Inhibitor Drugs: Analysis of Local Control, Toxicity, and Outcome in a Single Research Centre Case Study. Anticancer Research, 2021, 41, 5107-5116.	0.5	1
5	Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 695136.	1.3	6
6	Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study Cancer Treatment and Research Communications, 2021, 29, 100481.	0.7	1
7	Stereotactic Body Radiation Therapy Boost in Patients With Cervical Cancer Ineligible for Brachytherapy. Cancer Diagnosis & Prognosis, 2021, 1, 53-60.	0.3	4
8	Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study. In Vivo, 2020, 34, 1407-1413.	0.6	1
9	One-week vaginal brachytherapy schedule as exclusive adjuvant post-operative treatment in intermediate- and high-intermediate-risk endometrial cancer patients. Journal of Contemporary Brachytherapy, 2020, 12, 124-130.	0.4	5
10	Post-mastectomy immediate breast reconstruction and adjuvant radiotherapy: long term results of a mono institutional experience. Radiologia Medica, 2020, 125, 887-893.	4.7	10
11	What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?. Lung Cancer, 2020, 146, 263-275.	0.9	4
12	Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3ÂGy/fraction). Radiologia Medica, 2019, 124, 1324-1332.	4.7	6
13	Long term results of single high dose Stereotactic Body Radiotherapy in the treatment of primary lung tumors. Scientific Reports, 2019, 9, 15498.	1.6	14
14	Orbital Radiotherapy Plus Concomitant Steroids in Moderate-to-Severe Graves' Ophthalmopathy: Good Results After Long-Term Follow-Up. International Journal of Endocrinology and Metabolism, 2019, In Press, e84427.	0.3	11
15	<i>Lactobacillus brevis</i> CD2 for Prevention of Oral Mucositis in Patients With Head and Neck Tumors: A Multicentric Randomized Study. Anticancer Research, 2019, 39, 1935-1942.	0.5	55
16	Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience. Radiation Oncology, 2019, 14, 205.	1.2	16
17	Inoperable early-stage primary and early recurrent non-small cell lung cancer: outcomes of a mono-institutional experience using a moderate hypofractionated schedule. Radiologia Medica, 2019, 124, 58-64.	4.7	2
18	Two Cases of Capecitabine-Induced Ileitis in Patients Treated with Radiochemotherapy to the Pelvis and Review of the Literature. Journal of Gastrointestinal Cancer, 2018, 49, 538-542.	0.6	7

MAURIZIO VALERIANI

#	Article	IF	CITATIONS
19	Re-irradiation in lung disease by SBRT: a retrospective, single institutional study. Radiation Oncology, 2018, 13, 87.	1.2	12
20	Single nucleotide polymorphism of GSTP1 and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy. Radiation Oncology Journal, 2018, 36, 218-226.	0.7	6
21	Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term Outcomes. Anticancer Research, 2018, 38, 1671-1676.	0.5	3
22	Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 535-542.	0.6	21
23	Second cancer incidence in primary mediastinal Bâ€cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of longâ€term survivors. Hematological Oncology, 2017, 35, 554-560.	0.8	6
24	Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction. Clinical Genitourinary Cancer, 2017, 15, 520-525.	0.9	11
25	Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. Anti-Cancer Drugs, 2017, 28, 110-115.	0.7	6
26	Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up. Clinical Colorectal Cancer, 2017, 16, 58-64.	1.0	59
27	Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life―study. BMC Cancer, 2017, 17, 753.	1.1	24
28	Mono- and Bi-weekly Hypofractionated Radiation Therapy for the Treatment of Epithelial Skin Cancer in Very Elderly Patients. Anticancer Research, 2017, 37, 825-830.	0.5	14
29	Stereotactic Body Radiation Therapy in Primary and Metastatic Liver Disease. Anticancer Research, 2017, 37, 7005-7010.	0.5	5
30	A Case of Sinonasal Melanoma With Unusual Primary Exon 17 KIT D820G Mutation. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, e94-e97.	0.6	1
31	Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy. Radiation Oncology, 2016, 11, 78.	1.2	3
32	Renin-Angiotensin System Inhibitors Might Help to Reduce the Development of Symptomatic Radiation Pneumonitis After Stereotactic Body Radiotherapy for Lung Cancer. Clinical Lung Cancer, 2016, 17, 189-197.	1.1	25
33	Multifraction Radiotherapy for Palliation of Painful Bone Metastases: 20 Gy versus 30 Gy. Tumori, 2015, 101, 318-322.	0.6	6
34	Manipulation of radiation-induced bystander effect in prostate adenocarcinoma by dose and tumor differentiation grade: In vitro study. International Journal of Radiation Biology, 2015, 91, 166-171.	1.0	7
35	Role of salvage stereotactic body radiation therapy in post-surgical loco-regional recurrence in a selected population of non-small cell lung cancer patients. Anticancer Research, 2015, 35, 1783-9.	0.5	13
36	Stereotactic Body Radiation Therapy for Liver Lesions. A Single-institution Experience. Anticancer Research, 2015, 35, 4171-5.	0.5	0

#	Article	IF	CITATIONS
37	Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up. Anticancer Research, 2015, 35, 5693-700.	0.5	8
38	Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach. Anticancer Research, 2015, 35, 6239-45.	0.5	19
39	Image-Guided Hypofractionated Radiotherapy in Low-Risk Prostate Cancer Patients. BioMed Research International, 2014, 2014, 1-6.	0.9	4
40	Cytokines, Fatigue, and Cutaneous Erythema in Early Stage Breast Cancer Patients Receiving Adjuvant Radiation Therapy. BioMed Research International, 2014, 2014, 1-7.	0.9	42
41	Image guided intensity modulated hypofractionated radiotherapy in high-risk prostate cancer patients treated four or five times per week: analysis of toxicity and preliminary results. Radiation Oncology, 2014, 9, 214.	1.2	9
42	Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients. International Journal of Colorectal Disease, 2014, 29, 835-842.	1.0	6
43	Whole brain reirradiation and concurrent temozolomide in patients with brain metastases. Journal of Neuro-Oncology, 2014, 118, 329-334.	1.4	13
44	Fractionated stereotactic radiosurgery for patients with skull base metastases from systemic cancer involving the anterior visual pathway. Radiation Oncology, 2014, 9, 110.	1.2	24
45	Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy. Radiation Oncology, 2013, 8, 137.	1.2	18
46	Stereotactic radiosurgery in elderly patients with brain metastases. Journal of Neuro-Oncology, 2013, 111, 319-325.	1.4	48
47	Radiation therapy after breast reconstruction: outcomes, complications, and patient satisfaction. Radiologia Medica, 2013, 118, 1240-1250.	4.7	27
48	External-beam radiotherapy and/or HDR brachytherapy in postoperative endometrial cancer patients: clinical outcomes and toxicity rates. Radiologia Medica, 2013, 118, 311-322.	4.7	6
49	Image Guided Hypofractionated 3-Dimensional Radiation Therapy in Patients With Inoperable Advanced Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, e157-e163.	0.4	43
50	Clinical Outcomes of Single Dose Stereotactic Radiotherapy for Lung Metastases. Clinical Lung Cancer, 2013, 14, 699-703.	1.1	51
51	Hypofractionated Intensity-Modulated Simultaneous Integrated Boost and Image-Guided Radiotherapy in the Treatment of High-Risk Prostate Cancer Patients: A Preliminary Report on Acute Toxicity. Tumori, 2013, 99, 474-479.	0.6	3
52	Hypofractionated intensity-modulated simultaneous integrated boost and image-guided radiotherapy in the treatment of high-risk prostate cancer patients: a preliminary report on acute toxicity. Tumori, 2013, 99, 474-9.	0.6	3
53	Impact of Different Treatment Approaches on Pregnancy Outcomes in 99 Women Treated for Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, 755-761.	0.4	11
54	Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?. Radiation Oncology, 2012, 7, 129.	1.2	18

MAURIZIO VALERIANI

#	Article	IF	CITATIONS
55	Anti-Helicobacter Pylori Therapy in Primary MALT Lymphoma of Rectum. Tumori, 2012, 98, e105-e110.	0.6	4
56	Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy. Radiologia Medica, 2012, 117, 125-132.	4.7	10
57	A case report of metastatic atypical thymic carcinoid with ectopic ACTH production: locoregional control after adaptive radiation treatment. Tumori, 2012, 98, 172e-5e.	0.6	3
58	Frameless linac-based stereotactic radiosurgery (SRS) for brain metastases: analysis of patient repositioning using a mask fixation system and clinical outcomes. Radiation Oncology, 2011, 6, 158.	1.2	65
59	Role of radiation therapy in mycosis fungoides refractory to systemic therapy. European Journal of Dermatology, 2011, 21, 213-217.	0.3	5
60	Hypofractionated radiotherapy with or without IGRT in prostate cancer: preliminary report of acute toxicity. Anticancer Research, 2011, 31, 3555-8.	0.5	9
61	Fractionated stereotactic radiotherapy for skull base tumors: analysis of treatment accuracy using a stereotactic mask fixation system. Radiation Oncology, 2010, 5, 1.	1.2	70
62	Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer. BJU International, 2010, 106, 1458-1462.	1.3	11
63	Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. Journal of Neuro-Oncology, 2009, 91, 95-100.	1.4	90
64	Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. Journal of Neuro-Oncology, 2008, 88, 97-103.	1.4	195
65	Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. Anti-Cancer Drugs, 2006, 17, 969-975.	0.7	16
66	High-grade gliomas: results in patients treated with adjuvant radiotherapy alone and with adjuvant radio-chemotherapy. Anticancer Research, 2006, 26, 2429-35.	0.5	2
67	Pain evaluation and management: a survey of Italian radiotherapists. Supportive Care in Cancer, 2005, 13, 215-218.	1.0	3
68	Short course radiation therapy for elderly cancer patients Critical Reviews in Oncology/Hematology, 2003, 45, 305-311.	2.0	30